Century Therapeutics Announces Major Restructuring with Leadership Overhaul and Strategic Shift

Biotechnology firm Century Therapeutics has initiated a dramatic corporate restructuring, eliminating nearly half of its workforce and replacing key executives. The sweeping changes, announced on September 4, signal a complete strategic pivot for the company following the discontinuation of a Phase 1 oncology trial.

The restructuring includes the immediate departure of both the Chief Development Officer and Chief Financial Officer, alongside the elimination of 72 positions. This substantial reduction in personnel is designed to sharpen the company’s focus on its most promising development programs. The strategic shift moves Century Therapeutics away from oncology research and toward a dedicated concentration on autoimmune disease therapies.

Executive Communication and Investor Outreach

CEO Brent Pfeiffenberger presented the new strategic direction during the H.C. Read more...